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HIF-1-regulated vasoactive systems are differentially involved in
acute hypoxic stress responses of the developing brain of
newborn mice and are not affected by levetiracetam
Abstract
Hypoxia-inducible transcription factor-1 (HIF-1) is critically involved in adaptive endogenous
mechanisms to hypoxic brain injury by transcriptional activation of specific target genes that restore
oxygen supply. Exogenously, neuroprotective properties of levetiracetam (LEV) have been suggested in
experimental cerebral ischemia and epilepsy. We aimed to elucidate 1) effects of acute hypoxic distress
on HIF-1 and vasoactive target genes, and 2) effects of LEV on HIF-1-regulated mechanisms in the
brain at early developmental stages. To this end, we studied the impact of hypoxia in the presence or
absence of LEV on the O2-dependent HIF-1alpha subunit as well as on VEGF and iNOS in the
developing brain of normoxic and hypoxic mice. C57BL/6 mice (P0, P7) were treated with saline or
LEV (i.p.; 50 mg/kg) 1 h before exposure to either normoxia (21% O2; N) or hypoxia (8% O2 of 6 h; H)
without reoxygenation. HIF-1alpha was analyzed by Western blot and immunohistochemistry and
mRNA levels were quantified by TaqMan RT-PCR. Hypoxia led to prominent accumulation of cerebral
HIF-1alpha protein in cortical neurons and glial cells and significant up-regulation of VEGF mRNA at
P0 (N, 0.018+/-0.002, vs. H, 0.031+/-0.003, n=6; p<0.05) and P7 (N, 0.096+/-0.032, vs. H,
0.873+/-0.069, n=7; p<0.001). Interestingly, we detected a significant decrease of iNOS mRNA levels in
hypoxic brains. LEV treatment did not alter HIF-1alpha accumulation either in normoxic or hypoxic
brains (P0, P7). Moreover, significant changes of VEGF and NOS mRNA levels did not occur with the
exception that hypoxia-induced decreased iNOS levels were not observed in P0 brains. We conclude
that acute systemic hypoxia differentially affects expression of HIF-1-regulated vasoactive factors in the
newborn mouse brain. Of clinical importance, LEV treatment did not alter crucial HIF-1-regulated
neuroprotective mechanisms.
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Abstract 
Hypoxia-inducible transcription factor-1 (HIF-1) is critically involved in adaptive 
endogenous mechanisms to hypoxic brain injury by transcriptional activation of 
specific target genes that restore oxygen supply. Exogenously, neuroprotective 
properties of levetiracetam (LEV) have been suggested in experimental cerebral 
ischemia and epilepsy. We aimed to elucidate 1) effects of acute hypoxic distress on 
HIF-1 and vasoactive target genes, and 2) effects of LEV on HIF-1-regulated 
mechanisms in the brain at early developmental stages. To this end, we studied the 
impact of hypoxia in the presence or absence of LEV on the O2-dependent HIF-1α 
subunit as well as on VEGF and iNOS in the developing brain of normoxic and 
hypoxic mice. C57BL/6 mice (P0, P7) were treated with saline or LEV (i.p.; 50 mg/kg) 
1 h before exposure to either normoxia (21% O2; N) or hypoxia (8% O2 of 6 h; H) 
without reoxygenation. HIF-1α was analyzed by Western blot and 
immunohistochemistry and mRNA levels were quantified by TaqMan RT PCR.  
Hypoxia led to prominent accumulation of cerebral HIF-1α protein in cortical neurons 
and glial cells and significant up-regulation of VEGF mRNA at P0 (N, 0.018±0.002, 
vs. H, 0.031±0.003, n=6; p<0.05) and P7 (N, 0.096±0.032, vs. H, 0.873±0.069, n=7; 
p<0.001). Interestingly, we detected a significant decrease of iNOS mRNA levels in 
hypoxic brains. LEV treatment did not alter HIF-1α accumulation either in normoxic or 
hypoxic brains (P0, P7). Moreover, significant changes of VEGF and NOS mRNA 
levels did not occur with the exception that hypoxia-induced decreased iNOS levels 
were not observed in P0 brains. We conclude that acute systemic hypoxia 
differentially affects expression of HIF-1-regulated vasoactive factors in the newborn 
mouse brain. Of clinical importance, LEV treatment did not alter crucial HIF-1-
regulated neuroprotective mechanisms.  
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1. Introduction  
Acquired brain lesions as a consequence of perinatal hypoxia are significant causes 
of neonatal morbidity as well as of severe long-term disability including senso-motor 
disabilities, postneonatal epilepsy, cognitive and behavioral disturbances 
(Woodward et al., 2006). Neonatal hypoxic brain injury develops as sequelae of 
pulmonary immaturity, systemic hypoperfusion, disturbed cerebrovascular 
autoregulation as well as neonatal complications, e.g. asphyxia, sepsis, apnoic 
spells and seizures whereas currently no specific neuroprotective treatment is 
available. The complex hypoxia-induced neurotoxic cascade including excitotoxic, 
inflammatory and metabolic pathways sustains secondary neurodegeneration during 
reoxygenation period (Jensen et al., 2006). Of note, regional and cellular 
vulnerability to hypoxia is age-specific and determined by distinct developmental 
factors including paracrine metabolic and vascoactive pathways as well as growth 
factors (Jensen, 2006). In this context, hypoxia-inducible transcription factor-1 (HIF-
1) has been characterized as one of the most important mediators of the molecular 
response to brain hypoxia as studied in adult (Stroka et al., 2001; Shao et al., 2005) 
and newborn rodents (Bergeron et al., 2000; Bernaudin et al., 2002). HIF-1 protein is 
a heterodimer consisting of an α- and β-subunit that belong to the basic-helix-loop-
helix (bHLH)/PAS transcription factors. HIF-1 is rapidly degraded by the ubiquitin-
proteasome pathway under normoxia. In contrast, hypoxia triggers stabilization and 
heterodimerization of the HIF-1α:HIF-1β complex that in turn binds to hypoxia 
response elements of numerous specific HIF-1 target genes modifying oxygen and 
energy supply, e.g. by activation of vasoproliferative and vasoactive effects (e.g. 
vascular endothelial growth factor, VEGF; inducible NO synthase, iNOS), glucose 
utilization and cell survival (Fandrey et al., 2006). The understanding of biological 
processes influenced by HIF-1 during very early developmental stage due to acute 
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hypoxia is still incomplete. This process is of special interest as efficacy of putative 
neuroprotective targets is obviously limited to a short immediate time window after 
hypoxic injury (Bergeron et al., 2000). Whereas mainly protective effects of HIF-1 
(Bergeron et al., 2000; Chavez et al., 2002; Grimm et al., 2005; Siddiq et al., 2005) 
and specific target genes such as VEGF (Jin et al., 2002) or erythropoietin (Grimm 
et al., 2005) on cell survival have been emphasized, induction of apoptosis due to 
HIF-1 stabilization under severely hypoxic conditions has been described only 
recently (Helton et al., 2005). Moreover, neuroprotective as well as -toxic effects of 
the HIF-1-regulated inducible NO synthase isoform (iNOS) have been reported 
(Golde et al., 2002; Gustavsson et al., 2006; Pannu et al., 2006). These 
observations imply differential regulation of HIF-1-mediated systems on cell survival 
and cerebral blood flow regulation during impaired oxygenation and reoxygenation 
altering with developmental age and severity of hypoxic injury (Johnston et al., 1998; 
Curristin et al., 2002).  
Our study focused on cerebral HIF-1-mediated vasoactive hypoxic stress responses 
due to acute systemic hypoxia at very early stage of mouse brain development (P0, 
P7) approximately corresponding to that of the human brain at mid-gestation and 
near-term, respectively (Dobbing et al., 1979).  
Apart from hypoxic injury, different antiepileptic drugs are known to enhance 
vulnerability of the neonatal rodent brain to apoptotic neurodegeneration (Katz et al., 
2007). The anticonvulsive drug levetiracetam (LEV; (S)-α-ethyl-2-oxo-pyrrolidine 
acetamide) that binds to an integral synaptic vesicle membrane protein SV2A (Janz 
et al., 2003; Lynch et al., 2004) did not exert apoptosis in developing rat brain under 
normoxic conditions (Manthey et al., 2005). This drug also reduced cellular 
degeneration in rodent models of focal cerebral hypoxic ischemia (Hanon et al., 
2001) and epilepsy (Löscher et al., 1998; Marini et al., 2004). These observations 
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suggested neuroprotective properties of LEV. However, data on effects of LEV on 
hypoxic brain at early developmental stage and the interrelationship between LEV 
and HIF-1-dependent vasoactive mechanisms are not available.  
The purpose of the present study was to characterize HIF-1 protein and specific HIF-
1-dependent vasoactive gene responses of the developmental mouse brain at two 
different developmental stages (P0, P7) to severe short-term systemic hypoxia in the 
presence or absence of LEV. Additionally, we investigated effects of hypoxia and 
LEV on hypoxia-inducible NO synthases that are not under the control of HIF-1.  
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2. Results 
HIF-1α protein, HIF-1-regulated genes as well as hypoxia-inducible but HIF-1-
independent vasoactive factors were determined in developing mouse brains at P0 
and P7 upon exposure to severe systemic hypoxia with and without LEV treatment.  
 
Changing HIF-1α protein accumulation in the developing mouse brain during 
normoxia.  
Low levels of HIF-1α protein were detectable at normoxic conditions in whole brain 
lysates at both developmental ages P0 and P7 as assessed by Western blot analysis 
(Fig. 1) whereby signals were somewhat more prominent at P0 than at P7. 
Immunohistochemical staining of HIF-1α revealed protein expression in the 
developing cerebral cortex and hippocampus: HIF-1α protein was weakly expressed 
in normoxic mouse brains at P0 and P7 (Fig. 2; non-treated group). Positive stainings 
were predominantly found in neuron-like cells in the upper cortical layers (layers II/III) 
at both ages. Of note, HIF-1α-positive cells were more prominent in cerebral cortex at 
P0 (Fig. 2A, B) than P7 (Fig. 2I, J).  
 
Elevated HIF-1α protein levels in the developing mouse brain exposed to hypoxia. 
Systemic hypoxia (8% O2, 6 h) led to significant accumulation of HIF-1α protein in the 
developing mouse brain at both developmental ages (P0 and P7) compared to 
controls. Fig. 1 shows representative Western blot data of HIF-1α protein 
accumulation in hypoxic mouse brain compared to normoxic tissues demonstrating 
significant increase of HIF-1α in response to systemic hypoxia at P0 as well as at P7. 
As the developing cerebral cortex is highly vulnerable to hypoxia, we assessed 
spatial and cellular cortical HIF-1α expression by immunohistochemical analysis. We 
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detected a marked increase in the number and intensity of HIF-1α-positive cells 
throughout the cortex (Fig. 2, hypoxia group) and hippocampus (data not shown) of 
hypoxic brains compared to normoxic controls. The strong nuclear accumulation of 
HIF-1α in hypoxic brains was observed at P0 (Fig. 2E, F) and, more prominent, at P7 
in cortical layers II-VI (Fig. 2M, N). To identify HIF-1α-positive cells, we performed 
double immunostaining with anti-HIF-1α and anti-NeuN antibodies that revealed 
strong co-labelling (Fig. 3A, B) indicating that a significant proportion of developing 
cortical neurons increased HIF-1α stabilization during short-term systemic hypoxia. 
Additionally, several HIF-1α-positive cells in dorsal hippocampus were also positive 
for GFAP staining (Fig. 3C, D).  
 
Differential expression of HIF-1-regulated target genes in the hypoxic brain. 
To determine the functional activation of cerebral HIF-1α protein due to acute 
systemic hypoxia, we analyzed mRNA levels of vasoactive HIF-1 target genes in 
homogenates of developing mouse brains exposed to systemic hypoxia (8% O2) for 
6h. When exposed to reduced oxygenation, cerebral VEGF mRNA levels increased 
1.7-fold in the untreated P0 (p<0.05) and more strongly (9.1-fold), in the P7 animals 
(Fig. 4A; hypoxia group; p<0.001) compared to normoxic controls. Unexpectedly, 
cerebral mRNA levels for iNOS were significantly decreased in the hypoxic brains 
(P0, P7) when compared to normoxic controls (Fig. 4B, p<0.001).  
 
Expression of HIF-1-independent hypoxia-inducible genes.  
Gene expression of HIF-1-independent genes (eNOS, nNOS, caspase-3) known to 
be involved in the complex cascade of hypoxic fetal brain injury was not significantly 
different between normoxic and hypoxic brains of developmental age P0 and P7 
during the acute stage of hypoxic stress (Table 1).  
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Effects of LEV treatment during normoxia.   
To evaluate possible adverse effects, we compared cerebral HIF-1α protein and 
target gene expression upon saline- and LEV-treatment under normoxic conditions. 
LEV treatment did not significantly change HIF-1α protein accumulation in normoxic 
brains at both P0 and P7 developmental ages compared to non-treated tissues as 
assessed by Western blot (Fig. 1). Furthermore, immunohistochemical analysis did 
not show differences in the number and intensity of cortical HIF-1α-positive cells 
when comparing non-treated (Fig. 2 A, I), saline- (Fig. 2C, K) and LEV-treated 
animals (Fig. 2D, L) kept at normoxic conditions. Similarly, no significant changes of 
the cerebral expression of HIF-1-regulated (VEGF, Fig. 4 A, iNOS; Fig. 4 B, normoxia 
group) and HIF-1-independent but hypoxia-inducible genes (eNOS, nNOS, caspase-
3) (table 1) were observed 6 h after administration of LEV at a dose of 50 mg/kg to 
normoxic animals compared to controls.  
 
Effects of LEV treatment upon short-term systemic hypoxia.   
To study possible effects of LEV on hypoxia-induced alterations of cerebral HIF-1α 
protein and specific target gene expression, saline-treated and LEV-treated hypoxic 
mouse brains were compared. LEV did not modify HIF-1α protein accumulation in 
hypoxic brains at either P0 or P7 compared to non-treated hypoxic controls (Fig. 1). 
At the cellular level, intensity of HIF-1α-positive cells was not different between 
hypoxic LEV-treated brains (Fig. 2 H, P) and hypoxic non-treated (Fig. 2 E, M) and 
saline-treated tissues of the corresponding age group (Fig. 2 G, O) as assessed in 
hypoxic cerebral cortex (Fig. 2) and in hippocampus (data not shown) by 
immunohistochemical analysis. The hypoxia-induced increase of cerebral VEGF 
mRNA levels in animals exposed to hypoxia was similar in vehicle- and LEV-treated 
hypoxic animals of both P0 and P7 age group (Fig. 4A). Interestingly, hypoxia-
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induced decrease of iNOS mRNA levels was not present in the LEV-treated group at 
P0 (Fig. 4B) whereas there was a significant difference at P7 between hypoxic and 
normoxic brains of LEV-treated mice (Fig. 4B) similar to that observed in non-treated 
animals.  
Messenger RNA expression of HIF-1-independent genes (eNOS, nNOS, caspase-3) 
was found at similar levels in vehicle- and LEV-treated hypoxic brains at age P0 and 
P7 (Table 1) indicating no changes in response to LEV administered at a dose of 50 
mg/kg.  
To examine whether LEV enhances sensitivity to apoptotic cell death in normoxic and 
hypoxic brains were performed, Western blot analysis for anti-apoptotic (Bcl-2 and 
Bcl-XL) and pro-apoptotic (Bax) proteins (Fig. 5A). Although cerebral Bcl-2 signals 
were significantly lower at P0 than at P7 during normoxia and hypoxia (Fig. 5B), there 
was no significant difference in Bcl-2 accumulation between normoxic and hypoxic 
brains (Fig. 5A). LEV treatment did not induce significant changes of Bcl-2, Bcl-XL 
and Bax levels during normoxia and hypoxia at either P0 or P7 (Fig. 5A). 
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3. Discussion 
Upon reduced oxygen supply to very young mice (P0 and P7) we observed, firstly, 
that HIF-1 is rapidly induced in developing cortical neurons. Secondly, we noted that 
specific vasoactive target genes are differentially affected by this acute hypoxic 
distress. Thirdly, LEV-treatment did not alter accumulation of HIF-1α protein nor the 
vasoactive HIF-1 target gene VEGF indicating that LEV does not affect crucial 
endogenous modulators of cerebral adaptation to hypoxia at early stage of brain 
maturation. Interestingly, LEV prevented hypoxia-induced decrease of iNOS mRNA 
levels at P0 but not at P7 suggesting specific age-dependent differential effects. 
Finally, our data shows that LEV does not markedly change expression of HIF-1-
independent NOS in the normoxic or hypoxic newborn brain.  
 
HIF-1 is a readily available system of the developing mouse brain during short-term 
hypoxia. In contrast to chronic hypoxia (Curristin et al., 2002, Gustavsson et al., 
2006), limited data is available on HIF-1-dependent mechanisms during acute 
systemic hypoxia in absence of concomitant ischemia in the developing brain (Kaur 
et al., 2006). As short-term exposure to low oxygen is known to induce cytoprotective 
effects (Bergeron et al., 2000), we investigated effects of acute systemic hypoxia (8% 
O2 for 6 h) in mouse brain. Of note, this condition is stronger than the ones used in 
rodent models of hypoxic preconditioning (Bergeron et al., 2000; Bernaudin et al., 
2002), Moreover, HIF-1 responses at very early stages of brain development are 
critically involved in vasculogenesis and brain plasticity (Curristin et al., 2002). Our 
data strongly support that HIF-1 represents a rapidly responsive system of the 
developing brain during acute systemic hypoxia. The importance of immediate 
availability of HIF-1 is apparent from the observation of HIF-1α-positive cells in 
selectively vulnerable CNS regions even under normoxic conditions. Furthermore, 
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increased HIF-1α accumulation in hypoxic cortex at P7 compared to P0 implies a 
difference in cellular susceptibility to hypoxic distress at different developmental 
stages, an observation that might have future therapeutic implications when 
considering HIF-1 stabilization as a neuroprotective option (Siddiq et al., 2005).  
 
Acute hypoxia induced differential regulation of vasoactive HIF-1 target genes in 
developing mouse brain. Functional activity of HIF-1 in the developing brain is implied 
by the corresponding transcriptional VEGF elevation during the 6h exposure to 
hypoxia. The prominent increase of VEGF mRNA levels observed at both P0 and P7 
suggests rapid up-regulation of vasoactive mechanisms even at early stages of brain 
maturation in response to acute hypoxia. Obviously, the stage of brain development 
and the degree of cerebral hypoxia seem to determine the vasoactive response. In 
contrast, angiogenic and vasoproliferative effects of VEGF dominate during chronic 
hypoxia (Ogunshola et al, 2002; Zhu et al., 2003). Here we show significant VEGF 
mRNA up-regulation in hypoxic developing mouse brain indicating HIF-1-regulated 
modifications of the vasculature to maintain cerebral blood flow during acute hypoxia.  
Reports on effects of hypoxia on NOS activity in developing rodent brain are 
conflicting (Gonzalez-Barrios et al., 2002; Muramatsu et al., 2000). In agreement with 
others (Gonzalez-Barrios et al., 2002; Zhao et al., 2005), HIF-1-independent NOS 
mRNA levels were not altered during acute hypoxia in our model. Interestingly, we 
found a significant decrease of iNOS mRNA levels in hypoxic compared to normoxic 
brains in both P0 and P7 age groups similar to Zhao et al. (2005). In contrast, 
expression of iNOS was found by others (i) to increase only when reoxygenation 
occurred (Gonzalez-Barrios et al., 2002), or (ii) to be unchanged upon acute hypoxic 
ischemia in neonatal rat brain (Blumberg et al., 1999; van den Tweel et al., 2005). 
Thus, different experimental conditions might be an explanation of conflicting data on 
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the kinetics of NOS isoforms in response to hypoxia and reoxygenation. Since 
regulation of iNOS is modified e.g. in response to pro-inflammatory cytokines and 
endotoxins (Pannu et al., 2006), we cannot exclude interference of these factors in 
our experimental settings.   
 
LEV does not significantly alter endogenous HIF-1-regulated neuroprotective 
mechanisms. Whether the synaptic vesicle protein SV2A identified as the ligand of 
LEV (Lynch et al., 2004) is functionally influenced by hypoxia is not known. Here we 
present first data on the interrelationship between LEV and hypoxia-inducible 
endogenous neurotrophic factors in the developing mouse brain. Our data add to the 
evidence of neuroprotective properties of LEV (Hanon et al., 2001; Gu et al., 2004) 
by showing that LEV does not change hypoxic stress-induced mechanisms in 
developing mouse brain. There was no significant influence of LEV on HIF-1α protein 
stabilization and VEGF mRNA expression either under normoxia or hypoxia. LEV (50 
mg/kg) was used in a dose slightly above the anticonvulsant ED50 in rodents (Gower 
et al., 1992; Doheny et al., 1999) when sedative or other neurologic adverse effects 
(Löscher et al., 1998; Marini et al., 2004; Hanon et al., 2001; Gu et al., 2004) or 
enhanced antiepileptic drug-induced apoptosis (Manthey et al., 2005) are not 
expected from experimental studies of others. Presumed neuroprotective effects of 
LEV have been reported in dose ranges of 44-54 mg/kg (Hanon et al., 2001; Marini 
et al., 2004; Löscher et al., 1998). There is only one study on status epilepticus in 
adult rats suggesting dose-dependent protective effects of LEV administered at a 
high dosage of 1000 mg/kg on mitochondrial dysfunction (Gibbs et al., 2006), 
however, this was found exclusively during acute stage but not after prolonged status 
epilepticus (Gibbs et al., 2007). Additionally, potential effects of hypoxia on blood-
brain-barrier disturbances (Witt et al., 2005; Doheny et al., 1999) or on alterations of 
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multidrug transporter proteins (Potschka et al., 2004) could alter pharmacokinetics of 
LEV in the hypoxic CNS. 
Stabilization of HIF-1α protein and expression of HIF-1-dependent and independent 
genes were not significantly changed by LEV treatment (P0, P7) with the exception of 
iNOS mRNA in the very young group (P0). Considering that iNOS-derived NO is 
neuroprotective at low levels (Zhao et al., 2005), we speculate that the prevention of 
iNOS decrease in P0 brains treated with LEV maintains vascular function during 
acute hypoxic stress response. Additional studies on iNOS mRNA and protein 
kinetics during acute hypoxia and reoxygenation period are required to clarify the 
significance of LEV effects on iNOS and oxidative stress-induced inflammatory 
pathways (Marini et al., 2004) in relation to brain development.  
Apoptotic neurodegeneration assess by TUNEL staining was shown not to be 
exerted by LEV in neonatal rat brain (Manthey et al., 2005). In line with this, we found 
no influence of LEV treatment on determinants of apoptotic cell death at P0 and P7 
assessed by Western blot for anti-apoptotic Bcl-2, Bcl-XL and pro-apoptotic Bax 
proteins. Thus, susceptibility to cerebral apoptosis during acute hypoxia might not be 
exerted by LEV. Notably, significant lower Bcl-2 levels at P0 than P7 imply a different 
cellular apoptotic threshold during early stages of brain maturation (Mooney et al., 
2000).  
 
In summary, this study shows that HIF-1 represents a rapidly responsive and 
adaptable system of the newborn brain to severe short-term hypoxia at very early 
developmental stage, and that acute hypoxia differentially affects expression of HIF-
1-regulated vasoactive factors in newborn mouse brain. Accumulation of HIF-1α 
protein as well as expression of HIF-1-dependent and independent genes were not 
 14
altered by LEV treatment indicating no influence of LEV on crucial endogenous 
neuroprotective mechanisms of the developing newborn brain.  
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4. Experimental Procedure 
Animal experiments. C57BL/6 wild-type mice were exposed to systemic hypoxia 
(8% O2) without concomitant experimental ischemia at postnatal day 0 (P0, n=40) 
and day 7 (P7; n=38) providing a model for the preterm human neonate at mid-
gestation (P0) and the near-term neonate (P7) (Dobbing et al., 1979). Duration of 
hypoxic incubation was 6h (Hypoxic Workstation INVIVO2 1000, Biotrace 
International, U.K.). To enable adjustment to the hypoxic environment O2 deprivation 
was done gradually by decreasing the FiO2 from 21 to 8% in 2 % O2 steps during 60 
min before keeping the mice in continuous systemic hypoxia for additional 6 h. 
Controls were incubated under room air (P0, n=36; P7, n=38). Fifty-three out of the 
78 hypoxic mice and their corresponding normoxic controls (n=49) were treated with 
saline or LEV along the following regimen: Levetiracetam (LEV; (S)-α-ethyl-2-oxo-
pyrrolidine acetamide; UCB S.A., Preclinical CNS Research, Braine L´Álleud, 
Belgium) was injected i.p. in a single dose of 50 mg/kg (injection volume 0.1 ml) 1 h 
before incubation intervals (hypoxia: P0, n=15; P7, n=13; normoxia: P0, n=12; P7, 
n=13). Another group of 49 mice was treated with 0.1 ml saline i.p. 1 h before 
incubation (hypoxia: P0, n=13; P7, n=12; normoxia: P0, n=12; P7, n=12). After the 
incubation period brains were immediately dissected avoiding reoxygenation, frozen 
in liquid nitrogen and stored at -80°C until protein (3 brains per group) and mRNA 
extraction (6-9 brains per group). Another 3 brains per group were immediately 
embedded in paraformaldehyde for immunohistochemical examination. Animal 
experiments were performed according to protocols approved by the Kantonales 
Veterinäramt Zurich. 
RNA isolation and RT-PCR.  Total RNA was extracted using RNAzol-B isolation kit 
(WAK-Chemie Medical GmbH, Bad Homburg, Germany) according to the 
manufacturer´s instructions. RT-PCR was performed as described previously 
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(Trollmann et al., 2003). Commercial reagents (TaqMan PCR Reagent Kit, Perkin-
Elmer Corp.) and conditions were applied according to the manufacturer´s protocol. 
Porphobilinogen deaminase (PBGD) and ß-actin were used as housekeeping genes. 
The following primers and TaqMan probes based on published reports were used:  
PBGD, forward: 5´- ACAAGATTCTTGATACTGCACTCTCTAAG-3´;  
reverse: 5´- CCTTCAGGGAGTGAACAACCA -3´;  
TaqMan probe:   5´(FAM)- TCTAGCTCCTTGGTAAACAGGCTCTTCTCTCCA -(TAMRA)-3´;  
ß-actin, forward: 5´-ATGCTCCCCGGGCTGTAT -3´;  
reverse: 5´-TCACCCACATAGGAGTCCTTCTG -3´;  
TaqMan probe 5´(FAM)- ATCACACCCTGGTGCCTAGGGCG -(TAMRA)-3´;  
VEGF;  forward: 5´-GCACTGGACCCTGGCTTTACT -3´;  
reverse: 5´- ACTTGATCACTTCATGGGACTTCTG-3´;  
TaqMan probe: 5´(FAM)- CCATGCCCAGTGGTCCCAGGCTG-(TAMRA)-3´.  
iNOS, forward: 5´- CAGCTGGGCTGTACAAACCTT-3´;  
reverse: 5´-CATTGGAAGTGAAGCGTTTCG -3´;  
TaqMan probe: 5´(FAM)- CGGGCAGCCTGTGAGACCTTTGA-(TAMRA)-3´.  
eNOS, forward: 5´-GGAAATGTCAGGCCCGTACA -3´;  
reverse: 5´-GGTCTGAGCAGGAGACACTGTTG -3´;  
TaqMan probe: 5´(FAM)- TGAGCAGCACAAGAGCTACAAAATCCGA-(TAMRA)-3´.  
nNOS, forward: 5´- TGCACCACAGCCCATGG-3´;  
reverse: 5´-ATATAGTGATGGCCGACCTGAGG -3´;  
TaqMan probe: 5´(FAM)- TCAACTACATCTGTAACCACGTCAAGTACGCCAC-(TAMRA)-3´.  
Caspase 3, forward: 5´-AGATACCGGTGGAGGCTGACT -3´;  
reverse: 5´-GAACCACGACCCGTCCTTT -3´;  
TaqMan probe: 5´(FAM)- TTACTCTACAGCACCTGGTTACTATTCCTGGAGAAATTC-(TAMRA)-3´. 
 
Western blot analysis. Whole brains were homogenized in lysis buffer (10 mmol/l 
HEPES, 10 mmol/l KCl, 1.5 mmol/l MgCl2 , 1 mmol/l EDTA, 1 mmol/l dithiothreitol, 1 
mmol/l phenylmethylsulfonyl fluoride (PMSF), and 1 µg/ml protease inhibitors in 
distilled water). Samples were centrifuged at 4°C for 15 min. The supernatant was 
separated and kept at –80°C. The pellet (nucleus) was resuspended in buffer (25% 
glycerol, 20 mmol/l HEPES, 20 mmol/l KCl, 1.5 mmol/l MgCl 2 , 1 mmol/l EDTA, 1 
mmol/l dithiothreitol, 1 mmol/l PMSF, and 1 µg/ml protease inhibitors in destilled 
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water in distilled water), then high-salt buffer (20 mmol/l HEPES, 1 mmol/l EDTA, 1.5 
mmol/l MgCl 2 , 25% glycerol, 1.2 mol/l KCl, 1 mmol/l dithiothreitol, 1 mmol/l PMSF, 
and 1 µg/ml protease inhibitors in distilled water) was added. Thereafter, samples 
were centrifuged for 10 min at 4°C, and the supernatants (nuclear extracts) were kept 
at –80°C. Protein content was analyzed by commercial protein assay (BCA protein 
assay, Pierce Biological, Rockford, USA). Nuclear protein (40 µg) for analysis of HIF-
1α and cytoplasmic protein for analysis of pro- and anti-apoptotic proteins (40µg) 
were run on a 7.5% and 15% SDS-polyacrylamide gel, respectively, transferred to a 
nitrocellulose membrane, blocked in 5% nonfat milk-TBS for 90 min at room 
temperature. Afterwards membranes were incubated overnight at 4 °C with the 
polyclonal rabbit anti-HIF-1α antibody (Novus Biologicals, Littleton, CO; 1:1000) or 
the polyclonal rabbit anti-Bcl-2 (Delta Biolabs, LLC, CA; 1:200), anti Bcl-XL (Becton 
Dickinson Biosciences, Franklin Lakes, NJ, USA 1:1000) and anti-Bax antibody 
(Chemicon Int., Hampshire, UK; 1:500). After washing blots were incubated with a 
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature, 
followed by chemiluminescent detection. Three samples per group were analyzed, 
and blots were quantified densitometrically using the MCID program (Imaging 
Research). β-actin was used as a loading control.  
Immunohistochemistry. For immunohistochemical analysis coronal sections (3 µm 
thick) of paraformaldehyde-embedded mouse brains at the level of the dorsal 
hippocampus were performed (three brains per group). After heat-induced epitope 
retrieval, washing (TBS/Tween 20 0.05%) and blocking with normal goat serum 
sections were incubated with the monoclonal mouse anti-human HIF-1α antibody 
(α67, Novus Biologicals, Littleton, CO; 1:100) overnight at 4 °C. After washing 
sections were incubated with a biotinylated secondary antibody for 60 min. Antibody 
detection was amplified by using a commercial catalyzed signal amplification kit 
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(VECTASTAIN Elite ABC Kit; Linaris, Wertheim, Germany), based on the 
streptavidin-biotin-peroxidase reaction, according to manufacturer´s instructions. 
Reactions were visualized with DAB (Sigma, St. Luis, USA). To differentiate the type 
of HIF-1α-positive cells, sections were co-stained with HIF-1α and NeuN (neuronal 
marker) or GFAP (glial marker). The incubation of monoclonal mouse anti-NeuN 
(Chemicon Int., Hampshire, UK; 1:200) and rabbit anti-GFAP (Sigma, St. Luis, USA; 
1:100) was performed at room temperature for 2 h, followed by Alexa Fluor 488-
conjugated secondary antibody (Invitrogen, Eugene, USA; 1:500). For all incubations 
a humidified chamber was used. Negative controls were performed by omitting the 
primary antibody. All stainings were done in triplicate. Semiquantitative evaluation of 
immunohistochemical staining in cerebral cortex and hippocampus was performed 
using a 4 grade-scale by an observer who was blinded to the study groups.  
Statistical analysis. Data are expressed as mean±SEM. Statistical significance was 
determined by One-way ANOVA and Two-way ANOVA for repeated measurements 
(p-value<0.05).  
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Table 1. Expression of hypoxia-inducible HIF-1-independent genes in developmental mouse brain at P0 and P7 (mean±SEM) 
 
mRNA ratio* Non-treated 
normoxia vs hypoxia 
Vehicle-treated  
normoxia vs hypoxia 
LEV-treated 
normoxia vs hypoxia 
p 
P0 n=6/6   n=6/6 N=6/9  
nNOS/PBGD   0.84±0.08/0.74±0.08 0.77±0.04/0.74±0.06 0.70±0.04/0.98±0.07 ns 
eNOS/PBGD   0.04±0.02/0.04±0.01 0.07±0.02/0.04±0.01 0.05±0.004/0.02±0.003 ns 
caspase-
3/PBGD 
1.63±0.11/1.67±0.15  1.80±0.10/1.56±0.11 1.70±0.10/1.74±0.12 ns 
P7 n=7/6   N=6/6 N=7/7  
nNOS/PBGD   0.99±0.14/0.89±0.20 0.91±0.06/1.10±0.05 1.11±0.040/1.26±0.05 ns 
eNOS/PBGD   0.36±0.15/0.66±0.09 0.76±0.06/0.82±0.08 0.80±0.05/0.83±0.08 ns 
caspase-
3/PBGD 
1.75±0.14/1.58±0.08  2.01±0.14/2.05±0.31 2.12±0.16/1.89±0.17 ns 
    
  * Specific mRNA level in relation to PBGD mRNA concentration 
Legends to the tables and figures  
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Fig. 1 HIF-1α protein in mouse brains upon exposure to normoxia and severe 
systemic hypoxia (8% O2, 6 h) at P0 (left) and P7 (right) assessed by Western blot. 
Markedly increased cerebral accumulation of HIF-1α protein at both P0 and P7 
developmental stage due to hypoxia compared to normoxia. No changes of HIF-1α 
signals in response to LEV treatment administered i.p. at a dose of 50 mg/kg.  
 
Fig. 2 Immunohistochemical analysis of HIF-1α in developing mouse brain at P0 (A-
H) and P7 (I-P) exposed to hypoxia (P0, E-H; P7, M-P) or not (P0, A-D; P7, I-L). 
Pictures show representative stainings of cerebral cortex of non-treated, vehicle-
treated and LEV-treated animals.  
 
Fig. 3 Immunolabeling in hypoxic cerebral cortex (P7; A, B) and hippocampus (P7; C, 
D) showing localization of HIF-1α in neurons (A, B) and glial cells (C, D). A, B 
Cerebral cortex co-stained with anti-HIF-1α (A) and anti-NeuN (B) antibody and 
visualized with DAB (A) and Alexa Fluor 488 goat anti-rabbit IgG (B), respectively. C, 
D Cerebral cortex co-stained with HIF-1α (DAB; C) and GFAP (Alexa Fluor 488 goat 
anti-rabbit IgG; D). Scale bars = 20 µm (A, B), 50 µm (C, D). 
 
Fig. 4. VEGF (A) and iNOS mRNA expression (B) in relation to PBGD in non-
treated, vehicle- or LEV-treated (50 mg/kg, i.p.) mouse brain at P0 and P7 exposed 
to systemic hypoxia (8% O2, 6h). A. Significant up-regulation of VEGF mRNA levels 
in response to hypoxia at P0 and P7 compared to normoxic controls. No significant 
changes of VEGF expression in normoxic and hypoxic brains in response to LEV 
treatment. B. Significant decrease of iNOS levels during hypoxia at P0 and P7 
compared to normoxic controls. No significant changes of iNOS expression in 
normoxic and hypoxic brains in response to LEV treatment, except gene expression 
at P0 without significant difference between normoxic and hypoxic tissues.  
 
Fig. 5. A. Western blot analysis for anti-apoptotic (Bcl-2; Bcl-XL) and pro-apoptitic 
(Bax) proteins in saline- or LEV-treated developing mouse brains at P0 (lanes 5-8) 
and P7 (lanes 1-4) exposed to normoxia or acute systemic hypoxia. There were no 
significant differences in either Bcl-2 and Bcl-Xl or Bax protein contents between 
saline- and LEV-treated brains. B. Age-dependent difference in Bcl-2 levels 
(mean±SEM) normalized to β-actin assessed by densitometric analysis.  
 
